BioSpace News Archive

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Ardelyx management will participate in three upcoming investor conferences in September including:

Davis is the voice behind Mayo Clinic’s latest creative campaign “You Know Where to Go”

- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian , and chief marketing officer, Dennis Rosenberg , will participate in the following investor

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, today announced its Chief Financial Officer (CFO) Stephen Randall will retire after more than 10 years with Titan. As part of the Company’s succession planning process, Monique L. Delorme, currently Vice President, Finance at Titan, will be promote

Teva to Present New Data on AUSTEDO ® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

Imago BioSciences, Inc . (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that Hugh Young Rienhoff, Jr. M.D., chief executive officer, will present a corporate overview at two upcoming investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference Date: Tuesday, September 8 th 2020 Time: 2:20 p.m.

Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually. A live, audio webcast for this event will be available on the Investor Relations sectio

Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical proof-of-concept, as well as to expand the Company’s operations Board of Inversago strengthened with the appointment of three new directors MONTREAL--( BUSINESS WIRE )-- Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (CDN$47 million) Series B financing round le

Kadmon Holdings, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to belumosudil, the Company’s Rho-associated coiled-coil kinase 2 inhibitor, for the treatment of systemic sclerosis.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following investor conferences and medical meetings: American Academy of Otolaryngology – Head & Neck Surgery (AAO-HNS) 2020 Virtual Annua